Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Southeast Family Office Looks US-Wide for Medtech Deals

17 Aug

A family office based in the southeast USA focuses its investment interests in healthcare, real estate, energy, and IT. The firm makes equity investments ranging from early-stage to full on commercialization, but also provides debt and convertible loan financing. The firm generally looks for USA-based opportunities but may consider deals outside of the USA and has a track record of working with companies globally. The firm seeks to make approximately 6-10 investments per year.

In the life sciences, the firm has a strong interest in medical device and diagnostic companies. The firm considers healthcare IT opportunities to a lesser degree, and will not consider biopharma companies for the most part. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. The firm is very opportunistic regarding the company’s stage of development and will consider products that are both on- and off-market.

The firm is looking for privately held companies backed by an experienced management team. Companies should have a strong exit strategy, including having a direct line of contact with strategic or financial buyers. The firm is open to both leading and co-investing in a financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: China Investor Founds US VC to Invest in Seed Stage Life Science Deals

17 Aug

A California-based venture capital firm was founded in 2014 by a parent company based in China. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K, and hopes to invest more capital in later rounds (i.e. Series A to B) as follow on investments to portfolio companies. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Global Venture Firm Invests in Early Stage Digital Health Opportunities

17 Aug

A venture capital firm with offices worldwide closed a $500M fund in 2016. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm makes 1-2 USA-based and 1 China-based investments per year.

In the healthcare sector, the firm is mainly interested in healthcare IT opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm have included tools to improve physician workflow, healthcare AI applications, and wearable health trackers for a consumer market. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Venture Firm Invests in Therapeutics, Diagnostics and Devices in North America and Europe

17 Aug

A venture capital firm based in Europe with an additional office in New York manages €176 million in total assets across two funds. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€8million ($0.7million-$10million). The current fund aims to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 1: Corporate VC Firm Invests Early in Women’s Health, Life Science Tools, and Novel Drugs and Devices

10 Aug

The corporate venture / life science investment arm of a life science and medical equipment manufacturer invests from an evergreen fund. The firm prefers to invest at company formation / seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record, but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with regulatory affairs, market access and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Transatlantic Fund Looks Across USA and Europe for Medtech, Diagnostics and Healthcare IT

10 Aug

A transatlantic investment fund based in the Netherlands manages four healthcare technology funds. The firm focuses on investing in companies developing therapeutics, medical devices, diagnostics and digital health. The firm prefer to invest in clinical stage therapeutics companies and commercial stage diagnostics/medical technology companies. The investment size ranges from €5 million up to €30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm primarily invests in Europe-based diagnostic companies, and US-based medical device, diagnostics and digital health companies.

The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Multinational Pharma Looks Externally for Preclinical Neuro Platforms

10 Aug

A multinational pharmaceutical company headquartered in Japan with a US subsidiary division is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets.

The firm’s external R&D is focused on both neurodegerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is also interested in diabetes, immunology, and infectious diseases. The firm is seeking platform technology with new MOA such as gene therapy, stem cell therapy, and monoclonal antibody acting on new targets. The firm prefers early stage, pre-POC assets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com